Oncology Data Systems, Inc.

Oncology Data Systems, Inc. specializes in developing software tools specifically designed for radiation therapy. Their most common product category is radiation therapy software, which includes programs like MUCheck® and its various versions (e.g., MUCHECK V7.0, MUCHECK V8). These tools focus on validating and monitoring monitor unit (MU) calculations to help ensure precise and accurate radiation treatment delivery.

Oncology Data Systems, Inc. is based in the United States. Since the company operates within the U.S., its devices are subject to regulatory oversight by the FDA. The U.S. regulatory framework requires manufacturers to comply with specific requirements for software-based medical devices, including classification, premarket submissions (like 510(k)s), and unique device identification (UDI) registration.

Oncology Data Systems, Inc.’s devices are listed in the FDA’s 510(k) and UDI registries. The 510(k) process is used for Class II devices to demonstrate substantial equivalence to a predicate device, ensuring they meet safety and effectiveness standards. The UDI system assigns unique product identifiers to devices to improve tracking, reduce medical errors, and enhance regulatory oversight. Both registries are critical for transparency and compliance in the U.S. medical device landscape.

Oncology Data Systems, Inc.’s radiation therapy software devices are classified as Class II medical devices. This classification implies that while they pose moderate risk, they are not considered high-risk (Class III). As a result, these devices typically require premarket notification (510(k)) submissions to the FDA to demonstrate they are substantially equivalent to a legally marketed predicate device, ensuring they meet performance and safety standards without needing rigorous clinical trials.